Get the Stockscreener App
10.41
0.98%
-0.14
Sagimet Biosciences Inc stock is traded at $10.41, with a volume of 1.46M.
It is down -0.98% in the last 24 hours and up +33.59% over the past month.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$10.55
Open:
$10.45
24h Volume:
1.46M
Relative Volume:
1.26
Market Cap:
$648.00M
Revenue:
$2.00M
Net Income/Loss:
$-43.51M
P/E Ratio:
-7.76
EPS:
-1.3415
Net Cash Flow:
$-39.73M
1W Performance:
+9.16%
1M Performance:
+33.59%
6M Performance:
+102.85%
1Y Performance:
+36.21%
1-Day Range:
$10.28
$11.15
1-Week Range:
$9.07
$11.15
52-Week Range:
$4.50
$11.15
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
10.43 | 655.77M | 2.00M | -43.51M | -39.73M | -1.3415 |
VRTX
Vertex Pharmaceuticals Inc
|
515.73 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.26 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.59 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.75 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.20 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Initiated | Rodman & Renshaw | Buy |
| Feb-03-26 | Initiated | Guggenheim | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - marketbeat.com
Dimensional Fund Advisors LP Acquires 135,178 Shares of Sagimet Biosciences Inc. $SGMT - marketbeat.com
Sagimet Biosciences (SGMT) Institutional Ownership 2026 - marketbeat.com
Sagimet Biosciences (NASDAQ:SGMT) Cut to "Sell" at Wall Street Zen - marketbeat.com
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
SGMT (NASDAQ: SGMT) executive plans 350,987-share stock sale under Form 144 - Stock Titan
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - kalkine.com.au
Sagimet Biosciences (NASDAQ:SGMT) Given New $29.00 Price Target at Citizens Jmp - marketbeat.com
Citizens raises Sagimet stock price target to $29 on acne drug - Investing.com South Africa
Sagimet Biosciences (SGMT): Balyasny group discloses 5.93% ownership in Schedule 13G - Stock Titan
FDA Approves Sagimet Biosciences' IND for Phase 3 Denifanstat Acne Study - Kalkine Media
Sagimet Biosciences Receives US FDA Clearance for Phase 3 Acne Trial - marketscreener.com
Sagimet Biosciences Inc. (SGMT) Stock Price, News, Quote & History - ca.finance.yahoo.com
Form 8K Sagimet Biosciences Inc For: 13 August By Investing.com - Investing.com Nigeria
Sagimet gets FDA OK for late-stage acne trial (SGMT:NASDAQ) - Seeking Alpha
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat By Investing.com - Investing.com South Africa
Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst - marketbeat.com
FDA clears Sagimet’s phase 3 trial for acne treatment denifanstat - Investing.com
FDA clears Sagimet Biosciences to begin Phase 3 trial of denifanstat for acne - Investing.com
Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026 - TradingView
Sagimet Biosciences Announces FDA Clearance of IND for Phase 3 Denifanstat Acne Trial - Quiver Quantitative
Sagimet Plans Acne Trial With About 800 Patients, 450 Expected Adolescents - Stock Titan
Sagimet Biosciences director George Kemble sells $201,146 in shares By Investing.com - Investing.com Canada
Sagimet Biosciences director George Kemble sells $201,146 in shares - Investing.com
Sagimet Biosciences (NASDAQ:SGMT) Director Sells 20,206 Shares of Stock - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Given New $56.00 Price Target at Canaccord Genuity Group - marketbeat.com
Why is Sagimet Biosciences stock climbing today? By Investing.com - Investing.com Australia
Here's Why We're Not At All Concerned With Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation - simplywall.st
Why is Sagimet Biosciences stock climbing today? - Investing.com
Sagimet Biosciences (SGMT) insider plans 20,206-share stock sale after option exercise - Stock Titan
Sagimet Biosciences at Canaccord Genuity conference: acne pivot gains traction - Investing.com Nigeria
Sagimet Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Sagimet Making 'Good Progress' in Bringing Denifanstat to US Patients, Wedbush Securities Says - marketscreener.com
Sagimet Biosciences Q2 Results: EPS misses estimate, losses widen 18.75% YoY - scanx.trade
Sagimet Biosciences (NASDAQ:SGMT) Issues Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Sagimet Biosciences Announces Q2 2026 Financial Results and Updates Investor Presentation - Kalkine Media
Form 8K Sagimet Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Sagimet Reports $14 Million Q2 Net Loss and Phase 3 Acne Trial Plans - Quiver Quantitative
Sagimet Biosciences (SGMT) posts Q2 loss but funds acne pipeline through 2028 - Stock Titan
Sagimet Biosciences (SGMT) boosts cash to $257.6M with 2026 stock sale - Stock Titan
Sagimet Plans Phase 3 Trial for Potential Once-Daily Acne Treatment - Stock Titan
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Renaissance Technologies LLC Increases Stake in Sagimet Biosciences Inc. $SGMT - marketbeat.com
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BlackRock, Inc. Expands Stake in Sagimet Biosciences Inc (SGMT) With Strategic Add - GuruFocus
Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026 - Seeking Alpha
Sagimet Biosciences (SGMT) to Release Quarterly Earnings on Wednesday - MarketBeat
Exclusive BAC Article: Sagimet Biosciences; China NDA Acceptance Denifanstat For Acne, 2nd Half 2026 U.S. Study Initiation, MASH Drug Combination, And Catalysts (NASDAQ:SGMT) - Seeking Alpha
Sagimet Biosciences to present at Canaccord Gen... - Pluang
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kemble George | Director |
Aug 11 '26 |
Option Exercise |
6.36 |
20,206 |
128,510 |
82,367 |
| Kemble George | Director |
Aug 11 '26 |
Sale |
9.95 |
20,206 |
201,147 |
62,161 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):